Santhera Pharmaceuticals Holding Stock Fundamentals
| SPHDFDelisted Stock | USD 13.35 0.00 0.00% |
As of the 23rd of January, Santhera Pharmaceuticals has the Variance of 2.11, coefficient of variation of 10576.3, and Risk Adjusted Performance of 0.0119. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Santhera Pharmaceuticals, as well as the relationship between them. Please validate Santhera Pharmaceuticals standard deviation, as well as the relationship between the treynor ratio and kurtosis to decide if Santhera Pharmaceuticals is priced more or less accurately, providing market reflects its prevalent price of 13.35 per share. Given that Santhera Pharmaceuticals has variance of 2.11, we advise you to double-check Santhera Pharmaceuticals Holding's current market performance to make sure the company can sustain itself at a future point.
Santhera Pharmaceuticals' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Santhera Pharmaceuticals' valuation are provided below:Santhera Pharmaceuticals Holding does not presently have any fundamental trend indicators for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. Santhera |
Search Suggestions
| SPH | Suburban Propane Partners | Company |
| SPHIX | Fidelity High Income | Mutual Fund |
| SPHQ | Invesco SP 500 | ETF |
| SPHYDA | SP High Yield | Index |
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
CompetitionBased on the latest financial disclosure, Santhera Pharmaceuticals Holding has a Return On Equity of -13.1615. This is 45.09% lower than that of the Healthcare sector and 63.9% lower than that of the Biotechnology industry. The return on equity for all United States stocks is notably higher than that of the company.
Santhera Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Santhera Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Santhera Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Santhera Pharmaceuticals competition to find correlations between indicators driving Santhera Pharmaceuticals's intrinsic value. More Info.Santhera Pharmaceuticals Holding is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Santhera Pharmaceuticals' earnings, one of the primary drivers of an investment's value.Santhera Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Santhera Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Santhera Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Santhera Pharmaceuticals by comparing valuation metrics of similar companies.Santhera Pharmaceuticals is currently under evaluation in return on equity category among its peers.
Santhera Fundamentals
| Return On Equity | -13.16 | |||
| Return On Asset | -0.49 | |||
| Operating Margin | (386.18) % | |||
| Current Valuation | 60.45 M | |||
| Shares Outstanding | 61.81 M | |||
| Shares Owned By Insiders | 18.77 % | |||
| Shares Owned By Institutions | 3.50 % | |||
| Price To Earning | (6.80) X | |||
| Price To Book | 2.75 X | |||
| Price To Sales | 469.19 X | |||
| Revenue | (1.59 M) | |||
| Gross Profit | (5.36 M) | |||
| EBITDA | (34.57 M) | |||
| Net Income | (55.53 M) | |||
| Cash And Equivalents | 21.21 M | |||
| Cash Per Share | 0.43 X | |||
| Total Debt | 25.8 M | |||
| Current Ratio | 0.75 X | |||
| Book Value Per Share | (0.26) X | |||
| Cash Flow From Operations | (37.36 M) | |||
| Earnings Per Share | (1.68) X | |||
| Number Of Employees | 39 | |||
| Beta | 0.8 | |||
| Market Capitalization | 74.18 M | |||
| Total Asset | 91.12 M | |||
| Retained Earnings | (291 M) | |||
| Working Capital | 64 M | |||
| Current Asset | 74 M | |||
| Current Liabilities | 10 M | |||
| Z Score | -3.0 | |||
| Net Asset | 91.12 M |
About Santhera Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Santhera Pharmaceuticals Holding's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Santhera Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Santhera Pharmaceuticals Holding based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland. SANTHERA PHARMACEUTICALS operates under Biotechnology classification in the United States and is traded on PNK Exchange. It employs people.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in small area income & poverty estimates. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Santhera Pink Sheet
If you are still planning to invest in Santhera Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Santhera Pharmaceuticals' history and understand the potential risks before investing.
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Stocks Directory Find actively traded stocks across global markets | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |